Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-Dimethyltryptamine in humans

Biological Psychiatry

Volumn 39, Issue 9, 1996, Pages 784-795

  Strassman, Rick J ^a,c   Qualls, Clifford R ^a,b   Berg, Laura M ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c NONE   (Canada)

Author keywords

Drug abuse; Hallucinogens; N,N dimethyltryptamine; Schizophrenia; Serotonin receptors; Tolerance

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; N,N DIMETHYLTRYPTAMINE; PROLACTIN; PSYCHEDELIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0029970119     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00200-6     Document Type: Article

References (51)

1. Abramson HA, Rolo A, Sklarofksy B, et al (1960): Production of cross-tolerance to psychosis-producing doses of lysergic acid diethylamide and psilocybin. J Psychol 49:151-154.
2. Aghajanian GK (1994): LSD and phenethylamine hallucinogens: Common sites of neuronal action. In Pletscher A (ed), 50 Years of LSD: State of the Art and Perspectives of Hallucinogens. London: Parthenon.
3. 3H]-spiroperidol binding sites in human cortex? Life Sci 38:1251-1260.
4. Angrist B, Rosen J, Gershon S (1974): Assessment of tolerance to the hallucinogenic effects of DOM. Psychopharmacology 36:203-207.
5. Appel JB, Freedman DX (1968): Tolerance and cross-tolerance among psychotomimetic drugs. Psychopharmacology 13: 267-274.
6. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40:399-412.
7. 2 agonist DOI. Eur J Pharmacol 161:45-51.
8. Bagdy G, Calogero AE, Murphy DL, et al (1989): Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamopituitary-adrenocortical axis in conscious rats. Endocrinology 125:2664-2669.
9. Balestrieri A, Fontanari D (1959): Acquired and cross-tolerance to mescaline, LSD-25, and BOL-148. Arch Neurol Psychiatry 1:279-282.
10. 1C receptor mediated behaviour in rats following chronic treatment with 5-HT receptor agonists, antagonists or anti-depressants. Psychopharmacology 105:219-224.
11. Calogero AE, Bagdy G, Szemeredi K, et al (1990): Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary adrenal axis in the rat. Endocrinology 126:1888-1894.
12. 2 agonists. Brain Res 515:299-302.
13. Cole JM, Pieper WA (1973): The effects of N,N-dimethyltryptamine on operant behavior in squirrel monkeys. Psychopharmacology 29:107-112.
14. 2 site. J Neurosci 6:3669-3675.
15. Cooper SG, Schiff SR, Bridger WH (1981): Tolerance to the behavioral effects of N,N-dimethyltryptamine in mice. Biol Psychiatry 16:861-867.
16. 2 receptors. Biochem Pharmacol 41:1739-1744.
17. Di Renzo G, Amoroso S, Taglialatela M, et al (1989): Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. Eur J Pharmacol 162:371-373.
18. Freedman DX (1968): On the use and abuse of LSD. Arch Gen Psychiatry 18:330-347.
19. Freedman DX, Aghajanian GK, Ornitz EM, et al (1958): Patterns of tolerance to lysergic acid diethylamide and mescaline in rats. Science 127:1173-1174.
20. h: Intracellular studies in rat facial motoneurons. Synapse 13:1223-1234.
21. Gillin JC, Kaplan J, Stillman R, et al (1973): Failure of N,N-dimethyltryptamine to evoke tolerance in cats. Biol Psychiatry 7:213-220.
22. Gillin JC, Kaplan J, Stillman R, et al (1976): The psychedelic model of schizophrenia: The case of N,N-dimethyltryptamine. Am J Psychiatry 133:203-208.
23. 2 involvement in the mechanism of action of hallucinogenic drugs. Life Sci 35:2505-2511.
24. Hollister LE (1961): Clinical, biochemical and psychologic effects of psilocybin. Arch Int Pharmacodyn 80:42-52.
25. Isbell H, Belleville RE, Fraser HF, et al (1956): Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. Arch Neurol Psychiatry 76:468-478.
26. Isbell H, Wolbach AB Jr, Wikler A, et al (1961): Cross-tolerance between LSD and psilocybin. Psychopharmacology 2:147-159.
27. 2 receptors in P11 cells. J Pharmacol Exp Ther 259:423-429.
28. Kovacic B, Domino EF (1976): Tolerance and limited cross-tolerance to the effects of N,N-dimethyltryptamine (DMT) and lysergic acid diethylamide-25 (LSD) on food-rewarded bar pressing in the rat. J Pharmacol Exp Ther 197:495-502.
29. Krebs KM, Geyer MA (1994): Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats. Psychopharmacology 113:429-437.
30. 2 receptors by DOM treatment. Eur J Pharmacol 163:145-149.
31. 2 receptor agonists and antagonists on blood pressure, heart rate and sympathetic nerve activity. J Pharmacol Exp Ther 242:1152-1159.
32. 2 receptors in rat brain. Neuropsychopharmacology 2:81-87.
33. Mucciloi G, Ghè C, Di Carlo R (1991): Distribution and characterization of prolactin binding sites in the male and female rat brain: Effects of hypophysectomy and ovariectomy. Neuroendocrinology 53:47-53.
34. Pierce P, Peroutka SJ (1989): Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 98:118-122.
35. Rech RH, Tilson HA, Marquis WJ (1975): Adaptive changes in behavior after repeated administration of various psychoactive drugs. In Mandell AJ (ed), Neurobiological Mechanisms of Adaptation and Behavior. New York: Raven Press, pp. 263-286.
36. Rosenberg DE, Isbell H, Miner EJ, et al (1964): The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacology 5:217-227.
37. Sanders-Bush E, Burris KD, Knoth K (1988): Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 246:924-928.
38. Schlemmer RF Jr, Davis JM (1986): A primate model for the study of hallucinogens. Pharmacol Biochem Behav 24:381-392.
39. Schopohl J, Hauer A, Kaliebe T, et al (1986): Repetitive and continuous administration of human corticotropin releasing factor to human subjects. Acta Endocrinol 112:157-165.
40. 2 receptors in interneurons. Synapse 9:208-218.
41. Sibley DR, Benovic JL, Caron MG, et al (1987): Regulation of transmembrane signaling by receptor phosphorylation. Cell 48:913-922.
42. Spitzer R, Williams J, Gibbon M (1987): Structured Clinical Interview for DSM-III-R - Outpatient Version. New York: Biometric Research Department, New York State Psychiatric Institute.
43. Stafford P (1992): Psychedelics Encyclopedia, 3rd ed. Berkeley, CA: Ronin Press.
44. Strassman RJ, Qualls CR (1994): Dose-response study of N,N-dimethyltryptamine in humans. I: Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry 51:85-97.
45. Strassman RJ, Qualls CR, Uhlenhuth EH, et al (1994): Dose-response study of N,N-dimethyltryptamine in humans. II: Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98-108.
46. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94:213-216.
47. Trulson ME, Keltch GF (1985): Development of tolerance to repeated administration of 5-methoxy-N,N-dimethyltryptamine in rats. Eur J Pharmacol 108:33-37.
48. Walker RW, Mandel LR, Kleinman JE, et al (1979): Improved selective ion monitoring mass-spectrometric assay for determination of N,N-dimethyltryptamine in human blood utilizing capillary column gas chromatography. J Chromatogr Biomed Appl 162:539-546.
49. Wallach MB, Friedman E, Gershon S (1972): 2,5-Dimethoxy-4-methylamphetamine (DOM). A neuropharmacological examination. J Pharmacol Exp Ther 182:145-154.
50. Whitnall MH (1993): Regulation of the hypothalmic corticotropin-releasing hormone neurosecretory system. Progr Neurobiol 40:573-629.
51. Wolbach AB Jr, Isbell H, Miner EJ (1962): Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions. Psychopharmacology 3:1-14.